company background image
A1LN34 logo

Alnylam Pharmaceuticals BOVESPA:A1LN34 Stock Report

Last Price

R$82.54

Market Cap

R$213.3b

7D

2.7%

1Y

115.5%

Updated

23 May, 2025

Data

Company Financials +

Alnylam Pharmaceuticals, Inc.

BOVESPA:A1LN34 Stock Report

Market Cap: R$213.3b

A1LN34 Stock Overview

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. More details

A1LN34 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 52.4% below our estimate of its fair value

Earnings are forecast to grow 61.11% per year

Earnings have grown 19% per year over the past 5 years

Risk Analysis

Shares are highly illiquid


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Alnylam Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Alnylam Pharmaceuticals
Historical stock prices
Current Share PriceUS$82.54
52 Week HighUS$85.44
52 Week LowUS$41.29
Beta0.17
1 Month Change18.00%
3 Month Changen/a
1 Year Change115.51%
3 Year Change172.14%
5 Year Changen/a
Change since IPO103.05%

Recent News & Updates

Recent updates

Shareholder Returns

A1LN34BR BiotechsBR Market
7D2.7%1.7%-0.6%
1Y115.5%-7.0%4.6%

Return vs Industry: A1LN34 exceeded the BR Biotechs industry which returned -7.1% over the past year.

Return vs Market: A1LN34 exceeded the BR Market which returned 4.2% over the past year.

Price Volatility

Is A1LN34's price volatile compared to industry and market?
A1LN34 volatility
A1LN34 Average Weekly Movementn/a
Biotechs Industry Average Movement10.2%
Market Average Movement5.3%
10% most volatile stocks in BR Market9.8%
10% least volatile stocks in BR Market2.9%

Stable Share Price: A1LN34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine A1LN34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20022,230Yvonne Greenstreetwww.alnylam.com

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders.

Alnylam Pharmaceuticals, Inc. Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
A1LN34 fundamental statistics
Market capR$213.28b
Earnings (TTM)-R$1.53b
Revenue (TTM)R$13.29b
16.0x
P/S Ratio
-139.7x
P/E Ratio

Is A1LN34 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A1LN34 income statement (TTM)
RevenueUS$2.35b
Cost of RevenueUS$328.44m
Gross ProfitUS$2.02b
Other ExpensesUS$2.29b
Earnings-US$269.70m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.07
Gross Margin86.01%
Net Profit Margin-11.49%
Debt/Equity Ratio2,119.1%

How did A1LN34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/23 05:41
End of Day Share Price 2025/05/21 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Alnylam Pharmaceuticals, Inc. is covered by 61 analysts. 31 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Huidong WangBarclays
Emily BodnarBerenberg